Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group

@article{Singh2014ConsensusRF,
  title={Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group},
  author={Siddharth Singh and Chris Dey and Hagen F Kennecke and Walter I. Kocha and Jean Alfred Maroun and Peter Metrakos and Tariq Mukhtar and Janice L. Pasieka and Daniel Rayson and Corwyn Rowsell and Lucas Sid{\'e}ris and Ralph P. W. Wong and Calvin How Lim Law},
  journal={Annals of Surgical Oncology},
  year={2014},
  volume={22},
  pages={2685-2699}
}
Pancreatic neuroendocrine tumors (pNETs) are rare heterogeneous tumors that have been steadily increasing in both incidence and prevalence during the past few decades. Pancreatic NETs are categorized as functional (F) or nonfunctional (NF) based on their ability to secrete hormones that elicit clinically relevant symptoms. Specialized diagnostic tests are required for diagnosis. Treatment options are diverse and include surgical resection, intraarterial hepatic therapy, and peptide receptor… 
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.
Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.
TLDR
A comprehensive review of NF-PNETs with special emphasis on recent advances in diagnosis and management is provided.
What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review
TLDR
Giving the fact that the liver is generally the only metastatic site, surgery keeps a place of choice alongside medical therapies in the treatment of metastatic disease, but its modalities and extensions are still a matter of debate.
Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
TLDR
A comprehensive summary of the current evidence supporting the use of systemic treatment for patients with diagnosis of advanced and metastatic panNENs is provided, as well as to provide strategies for treatment selection and address challenges for Treatment selection and sequencing of therapy.
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
TLDR
To further define and clarify the utility, appropriateness, and the sequence of the growing list of available therapies for this patient population will require more high level evidence, it is important to thoroughly review emerging evidence and report major findings in frequent updates.
Surgical management of pancreatic neuroendocrine liver metastases.
TLDR
Standard surgical principles apply to hepatic surgery for NELM, namely prioritizing low central venous pressure anesthesia, minimizing blood loss, knowledge of liver anatomy, generous use of intraoperative ultrasound, as well as safe parenchymal transection techniques and practices to avoid bile leakage.
Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
  • A. Bilici
  • Medicine
    Asian Pacific journal of cancer prevention : APJCP
  • 2015
TLDR
Systemic chemotherapy, targeted therapies, and anti-secretory treatments for the management of patients with unresectable or metastatic pNETs are reviewed, summarized in the light of recent advances.
Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation
TLDR
There is still no unanimity about the best management of tumor smaller than 2 cm, although the relatively recent introduction of minimally invasive techniques (robotic) is a valuable option to deal with these tumors.
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
TLDR
A comprehensive review of the approved and investigational drugs in pNET is provided, and highlights the current concerns about treatment sequencing, but also provides an update of some of the present and future efforts for an improvement in the therapeutic algorithm of the disease.
Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET).
TLDR
Based on updated literature review, the treatment strategy determinants for p-NEN with LM are discussed and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 120 REFERENCES
Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
TLDR
A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways have recently shown promise, with recent trials showing treatment with the V EGFR tyrosine kinase inhibitor sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.
Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.
TLDR
Canadian consensus guidelines for the diagnosis and management of well-differentiated gastroenterohepatic NETS are updated and expanded, based on a consensus meeting held in Paris, France, in 2008 and are based on the most current literature.
Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
TLDR
Whether aggressive surgical intervention is indicated for PNETs and what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention are discussed and investigated.
Neuroendocrine tumors of the gastro-entero-pancreatic system.
TLDR
Advances in the therapy and development of centers of excellence which coordinate multicenter studies, are needed to improve diagnosis, treatment and therefore survival of patients with GEP NETs.
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.
TLDR
A number of recent advances regarding the molecular pathology, diagnosis, localization, and management of PETs are addressed including discussion of peptide-receptor radionuclide therapy and other novel antitumor approaches and a discussion of future directions and unsettled problems in the field.
Hepatic neuroendocrine metastases: does intervention alter outcomes?
Surgical treatment of non‐functioning pancreatic islet cell tumors
TLDR
Treatment of PETs often requires a multi‐modality approach; however, surgical resection remains the only curative therapy for localized (non‐metastatic) disease.
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
TLDR
The tumor–node–metastasis proposal for foregut NETs of the stomach, duodenum, and pancreas that was designed, discussed, and consensually approved at this conference is reported.
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
TLDR
The natural history of this disease is invariably attended by a long history of vague abdominal symptoms, a series of visits to a primary care practitioner, and referral to a gastroenterologist, often with a misdiagnosis of IBS, so a greater index of suspicion and a carcinoid tumor profile screen are warranted.
Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™
TLDR
These guidelines discuss the diagnosis and management of neuro endocrine tumors and special considerations relating to these tumors; important updates include expanded information on octreotide use and a new algorithm on neuroendocrine tumors of unknown primary.
...
1
2
3
4
5
...